Centessa Pharmaceuticals (NASDAQ:CNTA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting [Yahoo! Finance]
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis [Yahoo! Finance]